An in vivo multimodal feasibility study in a rat brain tumour model using flexible multinuclear MR and PET systems

Background

In addition to the structural information afforded by ¹H MRI, the use of X-nuclei, such as sodium-23 (²³Na) or phosphorus-31 (³¹P), offers important complementary information concerning physiological and biochemical parameters. By then combining this technique with PET, which provides valuable insight into a wide range of metabolic and molecular processes by using of a variety of radioactive tracers, the scope of medical imaging and diagnostics can be significantly increased. While the use of multimodal imaging is undoubtedly advantageous, identifying the optimal combination of these parameters to diagnose a specific dysfunction is very important and is advanced by the use of sophisticated imaging techniques in specific animal models.

Methods

In this pilot study, rats with intracerebral 9L gliosarcomas were used to explore a combination of sequential multinuclear MRI using a sophisticated switchable coil set in a small animal 9.4 T MRI scanner and, subsequently, a small animal PET with the tumour tracer O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine ([¹⁸F]FET). This made it possible for in vivo multinuclear MR-PET experiments to be conducted without compromising the performance of either multinuclear MR or PET.

Results

High-quality in vivo images and spectra including high-resolution ¹H imaging, ²³Na-weighted imaging, detection of ³¹P metabolites and [¹⁸F]FET uptake were obtained, allowing the characterisation of tumour tissues in comparison to a healthy brain. It has been reported in the literature that these parameters are useful in the identification of the genetic profile of gliomas, particularly concerning the mutation of the isocitrate hydrogenase gene, which is highly relevant for treatment strategy.

Conclusions

The combination of multinuclear MR and PET in, for example, brain tumour models with specific genetic mutations will enable the physiological background of signal alterations to be explored and the identification of the optimal combination of imaging parameters for the non-invasive characterisation of the molecular profile of tumours.

Dynamic susceptibility contrast parametric imaging using accelerated dual-contrast echo planar imaging with keyhole

BACKGROUND

Echo planar imaging (EPI) is one of the methods of choice in dynamic susceptibility contrast MRI (DSC-MRI) because it provides a sufficient temporal resolution. However, the relatively long readout duration of EPI often imposes limitations on increased spatial coverage or the use of multiple contrasts.

PURPOSE

To develop a DSC-MRI method using EPIK (EPI with keyhole) to provide dual-contrast (TE₁ and TE₂ ) information with a higher spatial coverage than EPI. To compare results from the community-standard EPI method and the proposed EPIK method.

STUDY TYPE

Prospective.

SUBJECTS

One healthy subject and 17 brain tumor patients.

FIELD STRENGTH/SEQUENCE

3 T/accelerated EPI and dual-contrast EPIK sequences.

ASSESSMENT

After an initial evaluation using healthy in vivo images, the use of the proposed method for DSC-MRI was verified with brain tumor patients. The parametric images (eg, CBF and CBV) and arterial input function (AIF), obtained from both the EPI and EPIK, were compared.

STATISTICAL TESTS

The ratio of AIF peak height of the proposed method to that of EPI was computed. The ratio computation was also performed for the time-to-peak (TTP) in the AIF curves. From the obtained CBF and CBV maps, the tumor-to-brain (TBR) ratio was also calculated for each imaging method and the results were compared.

RESULTS

For the same temporal resolution (1.5 sec), EPIK yielded dual-contrast (TEs of 13/33 msec) with an increased spatial coverage (24 slices) and less geometric distortions than EPI; EPI provided single contrast (TE of 32 msec) with 20 slices. The obtained parametric values (eg, AIF peak, TTP, and TBR) had similar characteristics between EPI and the proposed method.

DATA CONCLUSION

The dual-contrast data produced by EPIK in DSC-MRI allowed T₁ -corrected parametric images without the need of second contrast injection and an enhanced estimation of the AIF.

LEVEL OF EVIDENCE

1 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:628-640.